Vaccines
•47 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (47)
| Company | Market Cap | Price |
|---|---|---|
|
MRK
Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
|
$271.83B |
$108.84
-1.92%
|
|
PFE
Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
|
$145.83B |
$25.67
-0.85%
|
|
CVS
CVS Health Corporation
CVS administers vaccines across its pharmacy network, a direct service offering.
|
$99.69B |
$78.59
-3.40%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$55.24B |
$124.63
-0.52%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda markets vaccines (QDENGA) and maintains a vaccines-focused portfolio.
|
$50.48B |
$16.16
-1.04%
|
|
BNTX
BioNTech SE
BioNTech develops and sells vaccines, including its mRNA vaccine platform, a core direct product category.
|
$26.20B |
$109.00
+2.76%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$16.28B |
$41.83
+6.28%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$12.19B |
$24.54
+1.47%
|
|
RDY
Dr. Reddy's Laboratories Limited
Strategic emphasis on vaccines, including RSV vaccine programs.
|
$10.76B |
$12.91
-1.34%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$6.05B |
$46.60
-3.00%
|
|
IBRX
ImmunityBio, Inc.
Vaccine vectors and vaccines pipeline (hAd5 vectors targeting TAAs).
|
$5.22B |
$5.54
+40.13%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.83B |
$15.62
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$1.66B |
$40.99
+2.32%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.30B |
$8.00
+2.76%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor is developing a vaccine candidate via its StealthX platform in collaboration with Project NextGen.
|
$1.11B |
$24.39
+1.46%
|
|
CVAC
CureVac N.V.
The company is actively developing infectious disease vaccines using its mRNA backbone (Vaccines).
|
$1.05B |
$4.66
|
|
OPK
OPKO Health, Inc.
OPKO is advancing vaccines via EBV vaccine collaboration, a core vaccine development activity.
|
$1.02B |
$1.29
+0.78%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$817.67M |
$10.03
-0.10%
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$586.33M |
$10.99
+0.41%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is a WT1-targeted cancer vaccine, fitting the Vaccines category as a therapeutic vaccine approach.
|
$526.49M |
$4.09
-18.10%
|
|
OCGN
Ocugen, Inc.
OCU500 represents an inhaled mucosal vaccine platform with a COVID-19 vaccine IND.
|
$494.00M |
$1.69
+4.32%
|
|
NWBO
Northwest Biotherapeutics, Inc.
DCVax-L and DCVax-Direct are therapeutic vaccines for cancer, aligning with Vaccines.
|
$444.63M |
$0.30
|
|
AHG
Akso Health Group
Vaccine research centers planned (AIDS and Covid-19) within the strategy.
|
$381.12M |
$1.54
+0.65%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$169.72M |
$6.21
+1.22%
|
|
VXRT
Vaxart, Inc.
VXRT directly develops and advances vaccines (norovirus, COVID-19, avian influenza) using its VAAST oral vaccine platform.
|
$159.95M |
$0.70
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-801 is a live virus vaccine candidate for mpox/smallpox, placing Tonix in vaccines development with potential commercialization.
|
$150.25M |
$17.13
+7.74%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$134.79M |
$8.34
+6.79%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oravax Medical Inc., in which Oramed holds a majority stake, focuses on oral vaccines, making Vaccines a direct product category for the company.
|
$134.08M |
$3.37
+3.06%
|
|
FBIO
Fortress Biotech, Inc.
Fortress’ portfolio includes vaccine programs (Helocyte's Triplex CMV vaccine), aligning with Vaccines.
|
$110.69M |
$3.73
+7.04%
|
|
ANIX
Anixa Biosciences, Inc.
Breast and ovarian cancer vaccines constitute a direct vaccine product line.
|
$105.00M |
$3.21
-0.47%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Vaccines program (universal dengue vaccine) as an internal asset and potential product.
|
$95.54M |
N/A
|
|
INO
Inovio Pharmaceuticals, Inc.
Pipeline includes Ebola vaccine booster (INO-4201) and other vaccine approaches; company develops vaccines using DNA plasmids.
|
$84.50M |
$1.57
-0.94%
|
|
TVGN
Tevogen Bio Holdings Inc.
TVGN 489 and the TVGN vaccine program indicate vaccine development capabilities (T cell vaccine approach).
|
$66.11M |
$0.34
+2.73%
|
|
PDSB
PDS Biotechnology Corporation
PDS0101/Versamune HPV functions as a therapeutic cancer vaccine, aligning with the Vaccines category.
|
$44.36M |
$0.98
+4.21%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$33.08M |
$0.50
-3.10%
|
|
DYAI
Dyadic International, Inc.
Company has vaccine-related programs and antigen work (e.g., mpox ferritin nanoparticle vaccine antigen) via its platforms, aligning with vaccines.
|
$31.49M |
$0.85
-4.49%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Strategic collaboration on thermostable vaccines indicates vaccine development activity.
|
$30.39M |
$1.41
+1.08%
|
|
BRNS
Barinthus Biotherapeutics plc
Pipeline includes vaccines (VTP-500 MERS) and vaccine-focused platforms.
|
$29.52M |
$0.72
-0.68%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN311 and PMN400 indicate a vaccine development program targeting amyloid and alpha-synuclein epitopes.
|
$18.63M |
$8.62
-1.54%
|
|
IMNN
Imunon, Inc.
PlaCCine platform includes DNA-based vaccines (e.g., COVID-19 candidate), aligning with Vaccines.
|
$9.10M |
$4.16
+0.73%
|
|
BCTX
BriaCell Therapeutics Corp.
Bria-IMT Bria-OTS involve cellular vaccine approaches in cancer, aligning with Vaccines.
|
$8.08M |
$4.30
-4.12%
|
|
ALZN
Alzamend Neuro, Inc.
ALZN002 is described as a vaccine-based active immunotherapy approach for Alzheimer's.
|
$7.38M |
$2.33
+3.78%
|
|
EVAX
Evaxion Biotech A/S
Evaxion develops vaccines, including EVX-01 for cancer and multiple infectious-disease vaccine programs.
|
$6.38M |
$4.55
-5.01%
|
|
SNGX
Soligenix, Inc.
ThermoVax vaccine thermostabilization platform and RiVax vaccine program place Soligenix in Vaccines.
|
$6.04M |
$1.41
+5.22%
|
|
IMRN
Immuron Limited
Travelan IMM-124E prophylactic product aligns with vaccines/immune prophylaxis category.
|
$6.04M |
$1.08
+0.93%
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$3.03M |
$2.97
+4.21%
|
Loading company comparison...
Loading industry trends...
Loading research report...
